NewAmsterdam Pharma (NASDAQ:NAMS) Given Average Rating of “Buy” by Analysts

NewAmsterdam Pharma (NASDAQ:NAMS) has received a consensus recommendation of “Buy” from the six research firms that are currently covering the company, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy rating. The average 1-year target price among analysts that have covered the stock in the last year is $36.20.

A number of analysts have recently issued reports on NAMS shares. Royal Bank of Canada reiterated an “outperform” rating and set a $31.00 price objective on shares of NewAmsterdam Pharma in a research note on Thursday, September 5th. Piper Sandler reaffirmed an “overweight” rating and set a $37.00 price target on shares of NewAmsterdam Pharma in a research note on Monday, September 23rd. Scotiabank upped their price objective on shares of NewAmsterdam Pharma from $35.00 to $47.00 and gave the company a “sector outperform” rating in a research report on Wednesday, December 11th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $36.00 target price on shares of NewAmsterdam Pharma in a research report on Thursday, December 5th.

Insider Buying and Selling at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, major shareholder Nap B.V. Forgrowth sold 8,530 shares of the stock in a transaction on Friday, November 15th. The shares were sold at an average price of $25.02, for a total transaction of $213,420.60. Following the sale, the insider now directly owns 11,812,033 shares of the company’s stock, valued at approximately $295,537,065.66. This represents a 0.07 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Louise Frederika Kooij sold 45,000 shares of NewAmsterdam Pharma stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $15.72, for a total transaction of $707,400.00. The disclosure for this sale can be found here. Insiders have sold 353,542 shares of company stock worth $8,599,328 over the last quarter. 19.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Banque Cantonale Vaudoise acquired a new position in shares of NewAmsterdam Pharma during the second quarter valued at $38,000. Quarry LP boosted its stake in NewAmsterdam Pharma by 2,469.2% during the 3rd quarter. Quarry LP now owns 6,500 shares of the company’s stock valued at $108,000 after purchasing an additional 6,247 shares during the period. Barclays PLC boosted its stake in NewAmsterdam Pharma by 1,813.4% during the 3rd quarter. Barclays PLC now owns 7,596 shares of the company’s stock valued at $126,000 after purchasing an additional 7,199 shares during the period. Bellevue Group AG acquired a new stake in shares of NewAmsterdam Pharma in the third quarter valued at approximately $128,000. Finally, XTX Topco Ltd bought a new stake in shares of NewAmsterdam Pharma during the third quarter valued at approximately $187,000. 89.89% of the stock is currently owned by institutional investors.

NewAmsterdam Pharma Trading Up 1.2 %

Shares of NASDAQ:NAMS opened at $25.95 on Thursday. The business’s 50-day simple moving average is $21.72 and its 200 day simple moving average is $19.09. NewAmsterdam Pharma has a one year low of $10.50 and a one year high of $27.29.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.